Chemotherapy Compounding Labelling 
epicur
MARCH 12, 2024
Epicur Pharma’s Advisory Council member Ann Donoghue, DVM, MS shares her personal perspective on the important relationship between veterinary oncology and compounded medications used in chemotherapy treatments. Many of the presentations discussed the chemotherapies available to treat dogs.
European Pharmaceutical Review
DECEMBER 5, 2022
PSMAfore, is a Phase III, open-label, multi-centre, 1:1 randomised study comparing the efficacy and safety of Pluvicto to a change in ARPI in 469 patients with PSMA–positive mCRPC. Pluvicto is an intravenous radioligand therapy that combines a ligand, a targeting compound with lutetium-177, a therapeutic radionuclide.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MARCH 23, 2023
It is also being assessed in other tumour types and along with other Incyte pipeline compounds. Zynyz monotherapy showed a 52% objective response rate (ORR) in chemotherapy-naïve patients. We continue to study the potential of Zynyz in additional tumour types and in combination with other Incyte pipeline compounds.”
European Pharmaceutical Review
AUGUST 17, 2022
Radioligand therapy (RLT), which combines a targeting compound (ligand) with a therapeutic radioactive atom (radioisotope), is an emerging treatment approach that may offer an alternative treatment option for some cancer patients. Its licensing makes it the first diagnostic PSMA imaging tracer to receive this status in Great Britain.
European Pharmaceutical Review
OCTOBER 19, 2023
With alpha particles, you must be very careful how the drug is made to ensure that the compound remains stable between manufacturing and use. How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? What do you envision the future of radiopharmaceuticals to be like?
epicur
SEPTEMBER 13, 2023
However, the more closely we look at what it takes to compound an exact strength, the clearer it becomes standard dosages are more beneficial to both patients and veterinary practices. Exact strengths are compounded by a technician in capsules or tablets at traditional 503A pharmacies. milligram tablet and a 1.6 milligram tablet.
pharmaphorum
APRIL 20, 2021
One of the filings is to convert the ADC’s current conditional approval as a later-line therapy for urothelial cancer in patients previously treated with PD-1/L1 checkpoint inhibitors and platinum-based chemotherapy into a full approval. Both have been granted an FDA priority review with an action date of 17 August.
Expert insights. Personalized for you.
52 
Let's personalize your content